Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 11/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 5/20 | 0.41 |
| ▸ | JAK3 | P52333 | 4/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28041187 | 0.79 | SYK (0.47) | MAPK1JAK2JAK3IRAK4SYK | |
| SCHEMBL12401437 | 0.78 | MAPK1 (0.59) | MAPK1RIPK1ALOX5APFEN1 | |
| SCHEMBL2277443 | 0.76 | JAK3 (0.51) | JAK3IRAK4SYK | |
| SCHEMBL2277435 | 0.76 | JAK3 (0.51) | JAK3IRAK4SYK | |
| SCHEMBL2277592 | 0.76 | JAK3 (0.51) | JAK3IRAK4SYK | |
| SCHEMBL3398616 | 0.74 | JAK3 (0.38) | MAPK1JAK2JAK3IRAK4SYK | |
| SCHEMBL3396337 | 0.74 | JAK3 (0.38) | MAPK1JAK2JAK3IRAK4SYK | |
| SCHEMBL27931478 | 0.74 | IRAK4 (0.51) | IRAK4SYKMKNK1MKNK2 | |
| SCHEMBL12372228 | 0.71 | MAPK1 (0.48) | MAPK1RIPK1ALOX5APFEN1JAK2 | |
| SCHEMBL12372627 | 0.69 | MAPK1 (0.51) | MAPK1RIPK1ALOX5APFEN1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | MAPK1 386/4885RIPK1 252/4885ALOX5AP 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.